Patent Assignment
Reel/Frame 019265/0712
First Lien Grant of Security Interest in United States Patents and Trademarks
Recorded: 2007-05-10
Received: 2007-05-10
Pages: 18
Assignors
CHESTER VALLEY PHARMACEUTICALS, LLC
Executed: 2007-05-03
GRACEWAY PHARMACEUTICALS, LLC
Executed: 2007-05-03
Assignee
BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT
101 N. TRYON STREET, CHARLOTTE, NC, 28255, UNITED STATES
Covered Properties
(48)
Method and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,887 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,891 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,875 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,838 →
Method and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,882 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,870 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,876 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,889 →
Method and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,850 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,890 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,846 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,830 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,892 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,885 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,815 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,881 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,871 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,873 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,811 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,844 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,805 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,817 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,879 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,835 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application:
60/896,792 →
Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of lmiquimod therapy
Application:
60/900,550 →
PACKAGING FOR 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-c] QUINOLIN-4-AMINE-CONTAINING FORMULATION
Application:
11/530,935 →
Immune Response Modifier Formulations
Application:
60/807,669 →
Oral osmotic drug delivery system
Application:
11/432,661 →
Intermediates for Imidazonaphthyridines
Application:
11/276,074 →
Imidazonaphthyridines
Application:
11/188,418 →
Imidazonaphthyridines
Application:
11/004,674 →
Process for Preparing Imidazoquinolinamines
Application:
10/974,258 →
Imidazonaphthyridines
Application:
10/824,232 →
Treatment for basal cell carcinoma
Application:
10/808,004 →
Process for Preparing 1-Substituted, 2-Substituted 1H-Imidazo[4,5-C]Quinolin-4-Amines
Application:
10/731,826 →
Process for Preparing Imidazoquinolinamines
Application:
10/624,014 →
Process for Preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-C)Quinolin-4-Amines
Application:
10/436,905 →
Imidazonaphthyridines
Application:
10/406,181 →
Urea Substituted Imidazoquinolines
Application:
10/370,800 →
Process for Preparing Imidazoquinolinamines
Application:
10/360,210 →
Process for Preparing Imidazoquinolinamines
Application:
10/352,606 →
Urea Substituted Imidazoquinolines
Application:
10/352,604 →
Process for Preparing 1-Substituted, 2-Substituted 1H-Imidazo[4,5-C]Quinolin-4-Amines
Application:
10/238,661 →
2 -Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Napthyridin-4 Amine
Application:
10/185,387 →
Process for Preparing Imidazoquinolinamines
Application:
10/180,678 →
Urea Substituted Imidazoquinolines
Application:
10/028,255 →
Process for Preparing 1-Substituted, 2-Substituted 1H-Imidazo [4, 5-C] Quinoline-4-Amines
Application:
09/974,038 →